Lunec J - Search Results

1

Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53^WT Uterine Leiomyosarcoma.

Chamberlain V, Drew Y, Lunec J. Chamberlain V, et al. Among authors: lunec j. Cancers (Basel). 2021 Dec 21;14(1):14. doi: 10.3390/cancers14010014. Cancers (Basel). 2021. PMID: 35008180 Free PMC article.

2

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.

Franklin M, Gentles L, Matheson E, Bown N, Cross P, Ralte A, Gilkes-Immeson C, Bradbury A, Zanjirband M, Lunec J, Drew Y, O'Donnell R, Curtin NJ. Franklin M, et al. Among authors: lunec j. Cancer Med. 2018 Sep;7(9):4744-4754. doi: 10.1002/cam4.1724. Epub 2018 Aug 14. Cancer Med. 2018. PMID: 30109783 Free PMC article.

3

ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma.

Wu CE, Koay TS, Esfandiari A, Ho YH, Lovat P, Lunec J. Wu CE, et al. Among authors: lunec j. Cancers (Basel). 2018 Dec 20;11(1):3. doi: 10.3390/cancers11010003. Cancers (Basel). 2018. PMID: 30577494 Free PMC article.

4

WIP1 Inhibition by GSK2830371 Potentiates HDM201 through Enhanced p53 Phosphorylation and Activation in Liver Adenocarcinoma Cells.

Wu CE, Huang CY, Chen CP, Pan YR, Chang JW, Chen JS, Yeh CN, Lunec J. Wu CE, et al. Among authors: lunec j. Cancers (Basel). 2021 Jul 31;13(15):3876. doi: 10.3390/cancers13153876. Cancers (Basel). 2021. PMID: 34359777 Free PMC article.

5

Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.

Esfandiari A, Hawthorne TA, Nakjang S, Lunec J. Esfandiari A, et al. Among authors: lunec j. Mol Cancer Ther. 2016 Mar;15(3):379-91. doi: 10.1158/1535-7163.MCT-15-0651. Epub 2016 Feb 1. Mol Cancer Ther. 2016. PMID: 26832796 Free PMC article.

6

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.

Zanjirband M, Edmondson RJ, Lunec J. Zanjirband M, et al. Among authors: lunec j. Oncotarget. 2016 Jun 28;7(26):40115-40134. doi: 10.18632/oncotarget.9499. Oncotarget. 2016. PMID: 27223080 Free PMC article.

7

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.

Zanjirband M, Curtin N, Edmondson RJ, Lunec J. Zanjirband M, et al. Among authors: lunec j. Oncotarget. 2017 Jul 15;8(41):69779-69796. doi: 10.18632/oncotarget.19266. eCollection 2017 Sep 19. Oncotarget. 2017. PMID: 29050241 Free PMC article.

8

Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.

Wu CE, Esfandiari A, Ho YH, Wang N, Mahdi AK, Aptullahoglu E, Lovat P, Lunec J. Wu CE, et al. Among authors: lunec j. Br J Cancer. 2018 Feb 20;118(4):495-508. doi: 10.1038/bjc.2017.433. Epub 2017 Dec 12. Br J Cancer. 2018. PMID: 29235570 Free PMC article.

9

TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response.

Wu CE, Koay TS, Ho YH, Lovat P, Lunec J. Wu CE, et al. Among authors: lunec j. Cancer Cell Int. 2019 Mar 7;19:53. doi: 10.1186/s12935-019-0768-3. eCollection 2019. Cancer Cell Int. 2019. PMID: 30899200 Free PMC article.

10

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.

Chessari G, Hardcastle IR, Ahn JS, Anil B, Anscombe E, Bawn RH, Bevan LD, Blackburn TJ, Buck I, Cano C, Carbain B, Castro J, Cons B, Cully SJ, Endicott JA, Fazal L, Golding BT, Griffin RJ, Haggerty K, Harnor SJ, Hearn K, Hobson S, Holvey RS, Howard S, Jennings CE, Johnson CN, Lunec J, Miller DC, Newell DR, Noble MEM, Reeks J, Revill CH, Riedinger C, St Denis JD, Tamanini E, Thomas H, Thompson NT, Vinković M, Wedge SR, Williams PA, Wilsher NE, Zhang B, Zhao Y. Chessari G, et al. Among authors: lunec j. J Med Chem. 2021 Apr 8;64(7):4071-4088. doi: 10.1021/acs.jmedchem.0c02188. Epub 2021 Mar 24. J Med Chem. 2021. PMID: 33761253

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

335 results

Search Page